Navigation Links
Questcor Pharmaceuticals to Present at the Leerink Swann Global Healthcare Conference on February 16, 2012

ANAHEIM, Calif., Feb. 10, 2012  /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at the Leerink Swann Global Healthcare Conference to be held on February 15-16, 2012 in New York.  Steve Cartt, Executive Vice President and Chief Business Officer, is scheduled to present an overview of the Company on Thursday, February 16, 2012 at 2:30 p.m. ET. 

A live webcast and subsequent archived replay of the presentation will be accessible at  The replay will be available for 90 days after the event.

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product, Acthar, helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the use of Acthar to treat systemic lupus erythematosus, or SLE, for which Acthar is approved as both a maintenance therapy and to treat exacerbations.  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.  In October 2011, Forbes magazine ranked Questcor number one in its annual rankings of America's Best Small Companies.  For more information, please visit

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Questcor Announces Third Quarter 2010 Earnings Release Date and Conference Call
2. Questcor Pharmaceuticals to Be Added to S&P SmallCap 600 Index
3. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on June 9, 2011
4. Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
5. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
6. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
7. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
8. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
9. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
10. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
11. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
Post Your Comments:
(Date:12/1/2015)... 2015  CardioCell LLC, a Stemedica Cell Technologies ... cardiovascular indications, intends to proceed with finalizing a ... from a Heart Failure Advisory Board comprising cardiology ... Board members . In a recent meeting members ... and efficacy data from CardioCell,s on-going chronic heart ...
(Date:12/1/2015)... 1, 2015 Cepheid (Nasdaq: CPHD ) ... the Piper Jaffray Healthcare Conference in New ... is reaffirming its outlook for the fourth quarter of ... to discussing longer term business model expectations. ...  "We continue to be the fastest growing company of ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... physicians, aesthetic practitioners and aesthetics professionals from Central America and abroad for the ... in Panama City, Panama Feb. 17-19, 2016. Testart will present and discuss new ...
(Date:11/30/2015)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), a leader in ... Business Act on Climate Pledge, alongside more than 140 companies ... Obama Administration to demonstrate an ongoing commitment to climate action ... COP21 Paris climate negotiations. ... Canada . --> BioAmber uses biotechnology to ...
Breaking Biology Technology:
(Date:11/12/2015)... Nov. 12, 2015  Arxspan has entered into ... and Harvard for use of its ArxLab cloud-based ... tools. The partnership will support the institute,s efforts ... chemical research information internally and with external collaborators. ... for managing the Institute,s electronic laboratory notebook, compound ...
(Date:11/10/2015)... NEW YORK , Nov. 10, 2015 /PRNewswire/ ... refers to behavioral biometrics that helps to identify ... prevent fraud. Signature is considered as the secure ... for the identification of a particular individual because ... offers more accurate results especially when dynamic signature ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has been ... provide preclinical development services to the National Cancer Institute ... will provide scientific expertise, modern testing and support facilities, ... preclinical pharmacology and toxicology studies to evaluate potential cancer ... The PREVENT Cancer Drug Development Program is an ...
Breaking Biology News(10 mins):